每经AI快讯,据晶泰科技官微消息,今天,晶泰科技宣布与新加坡国立癌症中心(NCCS)以及杜克-新加坡国立大学医学院(Duke-NUS)开展AI新药发现合作,晶泰科技将运用其AI和自动化实验驱动的多肽研发设计平台,针对NCCS选定的肾透明细胞癌全新靶点,发现并设计临床候选药物。(文章来源:每日经济新闻)
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.